Recent changes in lifestyle such as high-fat diet and inactivity have promoted a metabolic disorder titled syndrome X. At the moment, it is very rare in Vietnam but the prevalence of this syndrome is going to significantly increases in next decades. In Endocrinology and Diabetic Dept- Bach Mai Hospital, we found a 44 year-old patient, who met the basic criteria of the syndrome X: Hypertension, central obesity and high fasting serum Insulin. He has mild dyslipidemia. All members of his family, including his mother and his sister are also suffering from syndrome X with hypertension, obesity and overt diabetes mellitus. This patient was advised to have diet with caloric restriction and exercise to improve insulin resistance. He has been using gemfibrozil (Lopid) and metformin. After 2 months, he has lost 6 kilograms and felt better. His blood pressure was controlled without antihypertensive drugs
Metabolic Syndrome X ; diagnosis

No abstract available.
Humans ; *Metabolic Syndrome X ; *Prostatic Hyperplasia

No abstract available.
Humans ; *Metabolic Syndrome X ; *Prostatic Hyperplasia

No abstract available.
Female ; Humans ; Metabolic Syndrome X/*blood ; Thyrotropin/*blood

No abstract available.
Antioxidants/*metabolism ; Female ; Humans ; Male ; Metabolic Syndrome X/*blood

Exosomes are extracellular vesicles that contain molecules that regulate the metabolic functions of adjacent or remote cells. Recent in vitro, in vivo and clinical studies support the hypothesis that exosomes released from various cell types play roles in the progression of metabolic disorders including type 2 diabetes. Based on this concept and advances in other diseases, the proteins, mRNA, microRNA and lipids in exosomes isolated from biological fluids have been proposed as biomarkers in metabolic disorders. However, several problems with the development of clinically applicable biomarkers have not been resolved. In this review, the biologic functions of exosomes are briefly introduced, and we discuss the technical and practical pros and cons of different methods of exosome isolation for the identification of exosomal biomarkers of metabolic disorders. Standardization of preanalytical variables and isolation of high-purity exosomes from fully characterized biological fluids will be necessary for the identification of useful exosomal biomarkers that can provide insights into the pathogenic mechanisms of complications of metabolic syndrome and of whole-body metabolism.
Biomarkers* ; Diabetes Mellitus ; Exosomes* ; Extracellular Vesicles ; In Vitro Techniques ; Metabolic Diseases* ; Metabolic Syndrome X ; Metabolism ; MicroRNAs ; RNA, Messenger

Exosomes are extracellular vesicles that contain molecules that regulate the metabolic functions of adjacent or remote cells. Recent in vitro, in vivo and clinical studies support the hypothesis that exosomes released from various cell types play roles in the progression of metabolic disorders including type 2 diabetes. Based on this concept and advances in other diseases, the proteins, mRNA, microRNA and lipids in exosomes isolated from biological fluids have been proposed as biomarkers in metabolic disorders. However, several problems with the development of clinically applicable biomarkers have not been resolved. In this review, the biologic functions of exosomes are briefly introduced, and we discuss the technical and practical pros and cons of different methods of exosome isolation for the identification of exosomal biomarkers of metabolic disorders. Standardization of preanalytical variables and isolation of high-purity exosomes from fully characterized biological fluids will be necessary for the identification of useful exosomal biomarkers that can provide insights into the pathogenic mechanisms of complications of metabolic syndrome and of whole-body metabolism.
Biomarkers* ; Diabetes Mellitus ; Exosomes* ; Extracellular Vesicles ; In Vitro Techniques ; Metabolic Diseases* ; Metabolic Syndrome X ; Metabolism ; MicroRNAs ; RNA, Messenger

BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) is associated with dyslipidemia, obesity, and insulin resistance, which are the main features of metabolic syndrome. First, we examined the prevalence of metabolic syndrome among patients with NAFLD. We then compared the prevalence of metabolic syndrome in simple steatosis with that in nonalcoholic steatohepatitis (NASH). Finally, we sought to identify clinical factors associated with the stage of liver fibrosis. METHODS: From November 2002 to March 2004, we enrolled consecutive 25 patients with NAFLD from patients visiting outpatient clinic. The 17 controls were healthy persons who visited our health promotion center. We compared the clinical and biochemical data of the NAFLD group with those of the control group. Using histologic findings, we divided NAFLD into simple steatosis and NASH. We then compared the clinical and biochemical data of the simple steatosis group with those of the NASH group. RESULTS: Fourteen patients (14/25, 56%) had metabolic syndrome in the NAFLD group. There was no difference in the prevalence of metabolic syndrome between the simple steatosis (5/10, 50%) and the NASH group (9/15, 60%). We found significant differences in cardiovascular risk factors between the two groups, but homeostasis model assessment insulin resistance was the only significantly different factor between the simple steatosis group and the NASH group. In addition, no difference in histological features was found between NASH with metabolic syndrome and without metabolic syndrome. CONCLUSIONS: A considerable number of patients with NAFLD had metabolic syndrome. There was a close correlation between NAFLD and metabolic syndrome. We could not find any cardiovascular risk factors that could predict a severe fibrosis.
Adult ; English Abstract ; Fatty Liver/*complications ; Female ; Humans ; Male ; Metabolic Syndrome X/*complications ; Middle Aged

PURPOSE: Recent studies have reported the association between metabolic syndrome and benign prostatic hyperplasia. This study was conducted to evaluate the relation between metabolic syndrome and prostate-specific antigen (PSA). MATERIALS AND METHODS: From January 2004 to December 2007, a total of 4,115 male outpatients (aged 40 to 79 years) who visited the health care center at our medical center were examined. Eligible men were classified according to the presence or absence of metabolic syndrome and the number of components of the metabolic syndrome. The association between the sum of metabolic syndrome components and PSA level was evaluated. The association between each metabolic syndrome component and PSA level was also evaluated. RESULTS: The PSA level of metabolic syndrome patients was lower than that of the control group (p=0.022). An increased number of metabolic syndrome components was significantly associated with a linear, decreasing trend in PSA levels (p-trend=0.040). When a Pearson's correlation was performed, only obesity was inversely associated with PSA level in the metabolic syndrome group. There was no significant factor that was related to having a PSA level greater than or equal to 2.5 ng/ml. CONCLUSIONS: Metabolic syndrome should be considered as a factor associated with reduced PSA levels. If the patient with metabolic syndrome is obese, the PSA cutoff value should be lower than 4 ng/ml.
Delivery of Health Care ; Humans ; Male ; Metabolic Syndrome X ; Obesity ; Outpatients ; Prostate-Specific Antigen ; Prostatic Hyperplasia

No abstract available.
Adenoma/*diagnosis ; Colorectal Neoplasms/*diagnosis ; Female ; Humans ; Male ; Metabolic Syndrome X/*diagnosis ; Uric Acid/*blood